Search Results for: hepatitis C virus

December 22, 2016December 22, 2016

Combo of RNA Interference Therapies and Antiviral Agents Treat Hepatitis B in Early Study

Hepatitis B, News

Treatments combining Benitec Biopharma’s investigative agents — BB-101, BB-102 or BB-103 — with current standard of care may be a way of treating hepatitis B virus (HBV) infection, according to results obtained ... Read more

December 20, 2016December 20, 2016

Hepatitis C Therapy Sovaldi Can Adversely Interact with HIV Therapy Viread, Study Says

Hepatitis C, News

The hepatitis C drug Sovaldi (sofosbuvir) can adversely interact with the human immunodeficiency virus (HIV) drug Viread (tenofovir disoproxil), according to recent findings. Both drugs are manufactured and commercialized by Gilead ... Read more

December 15, 2016December 16, 2016

Health Professionals in Ethiopia Show Solid Knowledge of Hepatitis B in Hospital Survey

Hepatitis B, News

The majority of healthcare professionals working at University of Gondar Hospital in Ethiopia are knowledgeable of hepatitis B transmission and its risks, and the importance of a vaccination program — all important points for people ... Read more

November 29, 2016November 29, 2016

Gilead Sciences Canada Recognized for Developing Harvoni as Hepatitis C Therapy

Hepatitis C, News

Gilead Sciences Canada has been awarded this year’s Prix Galien Canada–Innovative Product Award for the development of Harvoni (ledipasvir/sofosbuvir), a once-daily combination pill for the treatment of chronic genotype 1 hepatitis ... Read more

November 22, 2016November 22, 2016

Research Discovery May Explain Why Interferon-Induced Therapies Fail for Hepatitis C Patients

Hepatitis C, News

Researchers at the University of Washington have discovered that the virus that causes hepatitis C is capable of manipulating infected liver cells from the host, blocking signaling pathways that can trigger ... Read more

November 15, 2016November 15, 2016

FDA Gives Gilead Sciences’ Vemlidy a Green Light for Hepatitis B Viral Treatment

Hepatitis B, News

Gilead Sciences’ Vemlidy (tenofovir alafenamide) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic hepatitis B virus (HBV) infection with compensated ... Read more

November 8, 2016November 8, 2016

Promising Phase 1 Data Reported for Chronic Hepatitis C Investigational Therapy

Hepatitis C, News

Phase 1 clinical trial results show that CoCrystal Pharma’s CC-31244, a potential new therapy for hepatitis C virus (HCV) infections, meets the criteria to qualify for further testing. The randomized, ... Read more

October 25, 2016October 25, 2016

Combo Anti-Viral Treatment for Chronic Hepatitis C Shows Efficacy in Phase 3 Studies

Hepatitis C, News

Top-line results from four global Phase 3 clinical studies (POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4), led by Gilead Sciences, showed that the combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) — inhibitors of viral activity — can ... Read more

October 6, 2016October 6, 2016

FDA Warns Risk of Hepatitis B Reactivating with Certain Antiviral Drugs for Hepatitis C

Hepatitis B, Hepatitis C, News

Earlier this week, the U.S. Food and Drug Administration (FDA) warned about serious risks for patients infected with the hepatitis B virus (HBV) and who are being treated with certain direct-acting antiviral ... Read more

September 27, 2016October 4, 2016

NICE Approves Epclusa to Treat More Genotypes of Hepatitis C

Hepatitis C, News

The U.K. National Health Service’s (NHS) National Institute for Health and Care Excellence (NICE) recently published a new draft guidance recommending Epclusa (sofosbuvir-velpatasvir), an anti-viral drug that offers patients with chronic ... Read more